Blockade of nerve growth factor (NGF) with antibodies is a promising strategy for treatment of chronic pain associated with osteoarthritis (OA). This narrative review describes the current status of NGF-blockade for the treatment of OA pain. We summarise briefly current evidence for the efficacy and risks of anti-NGF blockade. Two anti-NGF antibodies, tanuzemab and fasinumab, are in active development, with tanuzemabclose to completing Phase 3 trials in preparation for an application for approval for clinical use.